| Detailed information |
|---|
| CancerLivER ID | 2543 |
| Biomarker | TACSTD1, MYH4, PSPHL, CXCR4, N33, GMNN, MGP, RGS2, G1P2, AREG, EMP1, IFIT1, SPINK1, ADAMTS1, SLC2A3, EPHA3, GJA1, RDC1, KCNJ16, MX1, KRT23, THBD, MTHFD2, IFI44, IGF1, SGCE, SPARCL1, CYP3A5, ATP8B1 |
| Biomarker Name/Symbol (given in Publication) | TACSTD1, MYH4, PSPHL, CXCR4, N33, GMNN, MGP, RGS2, G1P2, AREG, EMP1, IFIT1, SPINK1, ADAMTS1, SLC2A3, EPHA3, GJA1, RDC1, KCNJ16, MX1, KRT23, THBD, MTHFD2, IFI44, IGF1, SGCE, SPARCL1, CYP3A5, ATP8B1 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential prognostic marker associated with HCC progression; but not validated on independent dataset |
| Experimental Condition | Early v/s Late HCV Cirrhosis |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in late cirrhosis than early cirrhosis (with more than 3 fold) |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 15108252 |
| Type of Biomarker | Prognostic |
| Pathway | NA |
| Cohort | 22 patients undergoing liver transplantation for end-stage hepatitis C (without interferon treatment within 6 months of transplant) and 9 patients undergoing liver transplantation for alcoholic cirrhosis and 10 control liver samples (HCV-negative); (1) 5 early HCV cirrhosis ; (2) 8 late HCV-cirrhosi |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Early v/s Late HCV Cirrhosis |
| Year of Publication | 2004 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |